IL33 and neoplasm: Intriguingly, whilst reduced tumour burden in compound mutant gp130F/F/IL33−/− mice correlated with a decreased prevalence of mast cells and M2 macrophages, there was broadly no difference in expression of ILC2 markers relative to single mutant gp130F/F or Il33−/− mice.